Lutetium Lu-177 vipivotide tetraxetan
Lutetium Lu 177 vipivotide tetraxetan is a PSMA-targeted radioligand that carries therapeutic radiation to selected prostate-cancer cells.
At a glance
- Evidence stage
- Approved use
- Regulatory status
- PLUVICTO has FDA-approved PSMA-positive metastatic prostate-cancer indications, including a July 2026 expansion to androgen-pathway-modulation-naive/sensitive disease with ARPI therapy.
- Research context
- Lutetium Lu 177 vipivotide tetraxetan is a PSMA-targeted radioligand that carries therapeutic radiation to selected prostate-cancer cells.
What this is
- Lutetium Lu 177 vipivotide tetraxetan is a PSMA-targeted radioligand that carries therapeutic radiation to selected prostate-cancer cells.
What this isn't
- A recommendation to use, prepare, combine, or administer a product
- Evidence that a related molecule or a differently formulated product has the same effects
Key terms
Lutetium Lu 177 vipivotide tetraxetan is a PSMA-targeted radioligand that carries therapeutic radiation to selected prostate-cancer cells.
The targeting component binds prostate-specific membrane antigen, while lutetium-177 delivers beta radiation that damages nearby cells. Selection depends on PSMA imaging and the clinical disease state. This is a radiopharmaceutical, not an interchangeable supplement peptide; it is also distinct from lutetium-177 products targeting somatostatin receptors in other tumors. Current FDA prescribing information.
Evidence limits
How to read the evidence
The July 2026 FDA expansion is broader than older summaries restricted to resistant disease after prior therapies. Nevertheless, PSMA positivity, disease category, and accompanying therapy remain essential boundaries. The reported progression endpoint should not be restated as established overall-survival improvement or cure, and the interim follow-up cannot define every late radiation-related risk. FDA expansion announcement; trial report.
Sources appraised 2026-10-28. Educational information; not medical advice. Study findings apply to the populations, preparations and outcomes described.
External sources and citations
Related peptides
Other published briefs in the same research family. Educational references only - not treatment recommendations.
5-Amino-1MQ
When a laboratory value changes but patient outcomes remain uncertain.
Open resourcePeptide brief5-Amino-1MQ / SLU-PP-332
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourcePeptide briefAbaloparatide
How abaloparatide fits into peptide therapeutics, osteoporosis care, and evidence-based bone health.
Open resourcePeptide briefAcetyl hexapeptide-8
Acetyl hexapeptide-8, also called Argireline, is a synthetic cosmetic peptide studied for the appearance of facial lines. Older publications may call the same ingredient acetyl hexapeptide-3.
Open resourcePeptide briefAcetyl octapeptide-3
Acetyl octapeptide-3 is a cosmetic peptide included in products marketed for facial expression lines. Evidence for a delivery system or mixture must be distinguished from evidence for this ingredient alone.
Open resourcePeptide briefAcetyl tetrapeptide-5
Acetyl tetrapeptide-5 is a cosmetic ingredient commonly associated with eye-area products. Laboratory activity is not the same as demonstrated reduction of under-eye puffiness in people.
Open resourceLearn the research basics
Foundational literacy pieces that help interpret evidence stage, product identity, and study design.
How to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceLiteracyWhy a biological mechanism is not a treatment promise
A practical explanation of why plausible pathways still need meaningful human-outcome evidence.
Open resourceLiteracyPeptide naming, aliases, and product identity
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourceLiteracyFrom preclinical finding to human evidence
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourceLiteracyFDA approved, compounded, and unapproved are not synonyms
A plain-language map of product categories that are often blurred in peptide discussions.
Open resourceLiteracyUnderstanding surrogate endpoints in peptide research
When a laboratory value changes but patient outcomes remain uncertain.
Open resourceWatch & read
Same-family videos and articles from the Articles & Media channel. Educational references only.
Preparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resourceArticleAn ingredient name is not a complete product
Why matching a molecule name does not establish sameness in approval, formulation, quality, or evidence.
Open resourceRelated articles
Same-family articles from the published library. Educational references only - not treatment recommendations.
Preparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resourceArticleAn ingredient name is not a complete product
Why matching a molecule name does not establish sameness in approval, formulation, quality, or evidence.
Open resource